Full Text (PDF) CME: Take the course for this article: AJP CME Course for August 2008: Selective Muscarinic Receptor Agonist Xanom... Alert me when this article is cited Alert me if a correction is posted Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Articles by Shekhar, A. Articles by Felder, C. C. PubMed Citation Articles by Shekhar, A. Articles by Felder, C. C. Related Articles

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

Objective: There are significant unmet needs in the treatment of schizophrenia, especially for the treatment of cognitive impairment, negative syndrome, and cognitive function. Preclinical data suggest that agonists with selective affinity for acetylcholine muscarinic receptors provide a potentially new mechanism to treat schizophrenia. The authors studied xanomeline, a relatively selective muscarinic type 1 and type 4 (M₁ and M₄) receptor agonist, to determine if this agent is effective in the treatment of schizophrenia. Method: In this pilot study, the authors examined the efficacy of xanomeline on clinical outcomes in subjects with schizophrenia (N=20) utilizing a double-blind, placebo-controlled, 4-week treatment design. Outcome measures included the Positive and Negative Syndrome Scale (PANSS) for schizophrenia, the Brief Psychiatric Rating Scale (BPRS), the Clinical Global Impression (CGI) scale, and a test battery designed to measure cognitive function in patients with schizophrenia. Results: Subjects treated with xanomeline did significantly better than subjects in the placebo group on total BPRS scores and total PANSS scores. In the cognitive test battery, subjects in the xanomeline group showed improvements most robustly in measures of verbal learning and short-term memory function. Conclusions: These results support further investigation of xanomeline as a novel approach to treating schizophrenia.

Related Articles:

Cholinergic Agonists as Novel Treatments for Schizophrenia: The Promise of Rational Drug Development for Psychiatry

Jeffrey A. Lieberman, Jonathan A. Javitch, and Holly Moore
Am J Psychiatry 2008 165: 931-936. [Full Text] [PDF]

This article has been cited by other articles:

				A New Treatment Pathway for Schizophrenia? Journal Watch Psychiatry, August 18, 2008; 2008(818): 2 - 2. [Full Text]

				J. A. Lieberman, J. A. Javitch, and H. Moore Cholinergic Agonists as Novel Treatments for Schizophrenia: The Promise of Rational Drug Development for Psychiatry Am J Psychiatry, August 1, 2008; 165(8): 931 - 936. [Full Text] [PDF]

				C. A. Tamminga Accelerating New Knowledge in Schizophrenia Am J Psychiatry, August 1, 2008; 165(8): 949 - 951. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2008 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us